List Results
Refine Search
Results by Topic
Results on Map
Search Details
Found 54 studies with search of: Open Studies | "Spondylitis, Ankylosing"
Include studies that are not seeking new volunteers.
Hide studies with unknown recruitment status.
  Display Options
Rank Status Study
1 Recruiting Progression of Spinal Fusion in Ankylosing Spondylitis
Condition: Spondylitis, Ankylosing
Intervention:
2 Recruiting A Study to Investigate the Use of Simponi® in Participants With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis (P06554)
Conditions: Arthritis, Rheumatoid;   Arthritis, Psoriatic;   Spondylitis, Ankylosing
Intervention: Drug: Simponi®
3 Recruiting A Two-Part 26-Week Study of Etoricoxib as Treatment for Ankylosing Spondylitis (AS) (MK-0663-108)
Condition: Spondylitis, Ankylosing
Interventions: Drug: Part I - etoricoxib 60 mg;   Drug: Part I - etoricoxib 90 mg;   Drug: Part I- naproxen 1000 mg;   Drug: Part I - Placebo to etoricoxib 60 mg;   Drug: Part I - Placebo to etoricoxib 90 mg;   Drug: Part I - Placebo to naproxen 500 mg;   Drug: Part II- etoricoxib 60 mg;   Drug: Part II- etoricoxib 90 mg;   Drug: Part II- naproxen 1000 mg;   Drug: Part II - Placebo to etoricoxib 60 mg;   Drug: Part II - Placebo to etoricoxib 90 mg;   Drug: Part II - Placebo to naproxen 500 mg
4 Unknown † Heart Function in Rheumatoid Arthritis and Ankylosing Spondylitis Pre and Post-TNF Blocker
Conditions: Arthritis, Rheumatoid;   Spondylitis, Ankylosing
Intervention: Drug: TNF blockers (infliximab, adalimumab, etanercept)
5 Unknown † Examination of Radiographic Progression, Efficacy and Safety of Long-Term Treatment With Infliximab in Patients With Ankylosing Spondylitis
Condition: Ankylosing Spondylitis
Intervention: Drug: infliximab
6 Unknown † Pilot Open Label Clinical Trial With Abatacept in Ankylosing Spondylitis
Condition: Ankylosing Spondylitis
Intervention: Drug: abatacept
7 Unknown † Open Label Clinical Trial With Rituximab (MabThera ®) in Ankylosing Spondylitis
Condition: Ankylosing Spondylitis
Intervention: Drug: rituximab
8 Recruiting Biologic Rheumatology Registry Across Canada (P02843 AM5)
Conditions: Arthritis, Rheumatoid;   Spondylitis, Ankylosing;   Arthritis, Psoriatic
Intervention: Drug: infliximab or golimumab
9 Recruiting Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
Condition: Ankylosing Spondylitis
Intervention:
10 Recruiting Genetic Determinants of Ankylosing Spondylitis Severity
Condition: Ankylosing Spondylitis
Intervention:
11 Recruiting Genetic Determinants of Ankylosing Spondylitis Severity - Longitudinal Study
Condition: Ankylosing Spondylitis
Intervention:
12 Not yet recruiting Effects of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) on RAdiographic Damage in Ankylosing Spondylitis
Condition: Ankylosing Spondylitis
Intervention: Drug: diclophenac
13 Unknown † Prednisolone in Active Ankylosing Spondylitis (AS)
Condition: Ankylosing Spondylitis
Intervention: Drug: prednisolone
14 Not yet recruiting European Ankylosing Spondylitis Infliximab Cohort (EASIC) Follow up Registration Study
Condition: Ankylosing Spondylitis
Intervention:
15 Recruiting Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Condition: Ankylosing Spondylitis
Intervention:
16 Recruiting Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Condition: Ankylosing Spondylitis
Intervention: Drug: adalimumab (Humira)
17 Recruiting Efficacy at 16 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Ankylosing Spondylitis (AS)
Condition: Ankylosing Spondylitis
Interventions: Biological: Secukinumab (75 mg);   Biological: Secukinumab (150 mg);   Biological: Placebo
18 Recruiting Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Conditions: Ankylosing Spondylitis;   Psoriatic Arthritis
Intervention:
19 Unknown † Health-Related Quality of Life and Disease-Related Costs: Comparison Between Ankylosing Spondylitis, Rheumatoid Arthritis and Systemic Lupus Erythematosus in Taiwan
Conditions: Rheumatoid Arthritis;   Systemic Lupus Erythematosus;   Ankylosing Spondylitis
Intervention:
20 Recruiting Assessment of the Response to Etoricoxib in Patients With Ankylosing Spondylitis (AS) and Inadequate Response to ≥2 NSAIDs
Condition: Ankylosing Spondylitis (AS) and Inadequate Response to ≥2 NSAIDs.
Intervention: Drug: Etoricoxib

Previous Page Studies Shown (1-20) Next Page (21-40)
† Indicates status has not been verified in more than two years
Save this search by bookmarking this page.
When you use your bookmark, the search will be performed again on the most recent collection of studies.
RSS Feeds for studies found by your search that were:
  First received in the last 14 days,  
  Last updated (includes received) in the last 30 days
  Download Options




Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services